Institute of Molecular and Cell Biology (IMCB)’s Post

Taking Vitamin A to improve your eyesight is not always recommended. Normally, our body uses vitamin A to make retinal cells that are important for central vision. The fatty by-products are then cleared by a protein called ABCA4. For patients with Stargardt disease, a rare genetic mutation in the ABCA4 gene stops the protein from doing its job. The result is a buildup of yellowish fatty clumps that can lead to loss of central vision and night blindness. Beverly Mok believes that RNA editing to correct a defective ABCA4 could potentially treat Stargardt – which currently has no known treatment. Prior to joining IMCB, Beverly amassed experience in nucleic acid editing technologies during her time at Harvard University with Prof David Liu. Beverly brings this expertise to her strong collaboration with clinician-scientist Xinyi Su to expand the toolbox for therapeutic RNA editing of Stargardt. Like many emerging young scientists at IMCB, Beverly is supported by a Young Investigator Research Grant awarded by the The National Medical Research Council (NMRC). Come find out how IMCB brings researchers and clinicians together to develop better treatments and improve human health! #IMCBastar #IMCBtalents #IMCBscience #RNAediting #geneediting #stargardtdisease

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics